Last edition
News about "Kaivan Khavandi"
GSK completes acquisition of RAPT Therapeutics
GSK has completed the acquisition of RAPT Therapeutics, adding ozureprubart, a long-acting anti-IgE monoclonal antibody, to its pipeline. The candidate is currently in phase-II(b) development for prophylactic protection against food allergens, strengthening GSK’s immunology portfolio.
Kaivan Khavandi | 05/03/2026 | By Akanki
Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK
Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.
Kaivan Khavandi | 25/02/2026 | By News Bureau | 147
GSK Wins EU Approval for Exdensur in Severe Asthma and CRSwNP
European Commission clears twice-yearly depemokimab for type 2 inflammation-driven severe asthma and chronic rhinosinusitis with nasal polyps, backed by positive Phase III SWIFT and ANCHOR data.
Kaivan Khavandi | 18/02/2026 | By News Bureau | 110
China Approves Trelegy Ellipta for Uncontrolled Asthma
China has approved Trelegy Ellipta for adults with uncontrolled asthma, extending its use beyond COPD and making it the only single-inhaler triple therapy for both conditions in the country.
Kaivan Khavandi | 27/01/2026 | By News Bureau | 161
Japan Approves Exdensur for Severe Asthma and Nasal Polyps
Japan has approved Exdensur (depemokimab) for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), marking the first ultra-long-acting biologic in the country, with approval supported by phase-III SWIFT and ANCHOR trial data demonstrating sustained efficacy with twice-yearly dosing.
Kaivan Khavandi | 07/01/2026 | By News Bureau | 263
China Approves Nucala from GSK for Adult COPD Treatment
China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.
Kaivan Khavandi | 06/01/2026 | By News Bureau | 249
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
Kaivan Khavandi | 29/10/2025 | By Dineshwori | 230
GSK Completes Acquisition of Efimosfermin from Boston Pharmaceuticals for USD 2 Billion
GSK has completed its acquisition of efimosfermin alfa, a Phase III-ready investigational therapy for serious liver diseases, from Boston Pharmaceuticals in a deal worth up to USD 2 billion.
Kaivan Khavandi | 09/07/2025 | By Mrinmoy Dey | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy